Abbott has good chemistry

Abbott is about as balanced as it gets in the pharmaceutical sector, and an increase in sales and profit is likely this year.

By Jim J. Jubak May 16, 2011 5:14PM
Jim JubakYou can certainly find stocks with a higher dividend yield than the 3.4% that Abbott Laboratories (ABT) paid when I added it to my dividend income portfolio on May 6. (It closed that day at $52.52.)

But I think you’ll be hard pressed to find a stock paying that much that has the same potential for very safe and steady growth. (See my recent post for my latest update of that portfolio.)

Abbott is among the most balanced of the big U.S. drug companies. Pharmaceuticals accounted for just 56% of sales
in 2010, with the rest coming from nutritional products (16%), diagnostic products (11%), and a vascular business (9%) that makes stents and catheters.

The drug business itself is diversified across existing and potential blockbusters, such as Humira and Kaletra, potential new drugs from the four new molecular entities in late stage development and the 20 that the company projects will be in Phase 2 or Phase 3 clinical trials by the end of 2011, and recent acquisitions that have expanded the company’s market share in emerging economies such as India. (57% of Abbott Laboratories’ sales now come from overseas.)

I think investors can pretty much count on an 8% increase in sales in 2011, and a slight increase in gross margins from the 60.2% gross margin of 2010.

Earnings growth of a little better than 10% is very likely for 2011. That earnings increase gives me a target price of $60 a share by the end of 2011. That would be roughly 12% price appreciation from the May 13 close of $53.49.

The combination -- 3.4% yield, 12% capital gains, and well above average safety -- makes this an attractive stock for my dividend income portfolio. And with current market volatility, indeed for any portfolio.

At the time of this writing, Jim Jubak didn't own shares of any companies mentioned in this post in personal portfolios. The mutual fund he manages, Jubak Global Equity Fund (JUBAX), may or may not own positions in any stock mentioned. The fund did not own shares of Abbott Laboratories as of the end of March. For a full list of the stocks in the fund as of the end of the most recent quarter, see the fund's portfolio here. 

0Comments

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

114
114 rated 1
278
278 rated 2
474
474 rated 3
641
641 rated 4
639
639 rated 5
663
663 rated 6
640
640 rated 7
499
499 rated 8
284
284 rated 9
122
122 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
COPCONOCOPHILLIPS9
TAT&T Inc9
VZVERIZON COMMUNICATIONS9
KOGKODIAK OIL & GAS Corp9
CVXCHEVRON CORPORATION8
More

VIDEO ON MSN MONEY

ABOUT

Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.